• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agency of Health Technology Assessment of Uruguay
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canada’s Drug Agency (CDA-AMC)
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA South
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Norwegian Medical Products Agency
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Regione Emilia Romagna
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply

Welcome to the international HTA database

CSV RIS
Showing [24443 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2024     National Institute for Health and Care Excellence (NICE) Nivolumab for adjuvant treatment of completely resected melanoma at high risk of recurrence in people 12 years and over (terminated appraisal). NICE technology appraisal guidance 980
2024     Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale (CIUSSS) [The mental health day hospital: drawing on the literature to define the service offer and enhance practice]
2024     NIHR Health Services and Delivery Research programme Reducing health inequalities through general practice: a realist review and action framework
2024     National Institute for Health and Care Excellence (NICE) Trastuzumab deruxtecan for treating HER2-mutated advanced non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal). NICE technology appraisal guidance 976
2024     Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale (CIUSSS) [To support the decision-making process concerning the end of an episode of care for adult users undergoing physical rehabilitation]
2024     NIHR Health Technology Assessment programme Prehospital early warning scores for adults with suspected sepsis: the PHEWS observational cohort and decision-analytic modelling study
2024     National Institute for Health and Care Excellence (NICE) Dabrafenib with trametinib for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and over. NICE technology appraisal guidance 977
2024     NIHR Health Technology Assessment programme Patient-reported outcome measures for monitoring primary care patients with depression: the PROMDEP cluster RCT and economic evaluation
2024     National Institute for Health and Care Excellence (NICE) Zanubrutinib with obinutuzumab for treating relapsed or refractory B-cell follicular lymphoma after 2 or more treatments (terminated appraisal). NICE technology appraisal guidance 978
2024     NIHR Health Technology Assessment programme Allopurinol and cardiovascular outcomes in patients with ischaemic heart disease: the ALL-HEART RCT and economic evaluation
2024     National Institute for Health and Care Excellence (NICE) Sirolimus for treating facial angiofibroma caused by tuberous sclerosis complex in people 6 years and over (terminated appraisal). NICE technology appraisal guidance 972
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: adjustment of antidepressants for the follow-up of a major depressive disorder or an anxiety disorder]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atezolizumab (NSCLC) – Benefit assessment according to §35a Social Code Book V]
2024     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Liquid biopsy utility in the colorectal cancer's management stages I-IV]
2024     NIHR Health Technology Assessment programme KardiaMobile 6L for measuring QT interval in people having antipsychotic medication to inform early value assessment: a systematic review
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Markerless real-time monitoring surface guided radiation therapy]
2024     National Institute for Health and Care Excellence (NICE) Atogepant for preventing migraine. NICE technology appraisal guidance 973
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Enfortumab vedotin (urothelial cancer, first line) – benefit assessment according to §35a Social Code Book V]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Measles: diagnosis and detection]
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Artificial intelligence-based diagnostic assistant test for acute myocardial infarction using 12-lead electrocardiogram data]
2024     National Institute for Health and Care Excellence (NICE) Selinexor with bortezomib and dexamethasone for previously treated multiple myeloma. NICE technology appraisal guidance 974
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (urothelial cancer, first line) – Benefit assessment according to §35a Social Code Book V]
2024     NIHR Health Technology Assessment programme Cost-effectiveness of bioimpedance-guided fluid management in patients undergoing haemodialysis: the BISTRO RCT
2024     Penn Medicine Center for Evidence-based Practice (CEP) Robot-assisted vs. laparoscopic surgery for cholecystectomy
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Laparoscopic and endoscopic cooperative surgery for gastrointestinal tumor]
2024     National Institute for Health and Care Excellence (NICE) Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and under. NICE technology appraisal guidance 975
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Binimetinib and encorafenib (NSCLC) – Benefit assessment according to §35a Social Code Book V]
2024     Canary Health Service [Molecular urine-based biomarkers for the diagnosis of urothelial carcinoma]
2024     The Regional Health Technology Assessment Centre (HTA-centrum) Benefits and risks of using laparoscopic ultrasonography versus intraoperative cholangiography during laparoscopic cholecystectomy for gallstone disease
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Endograft fixation]
2024     Center for Outcomes Research and Economic Evaluation for Health (C2H) [Cost-effectiveness evaluation of tezepelumab (Tezspire)]
2024     National Institute for Health and Care Excellence (NICE) Selinexor with dexamethasone for treating relapsed or refractory multiple myeloma after 4 or more treatments. NICE technology appraisal guidance 970
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atezolizumab (NSCLC, adjuvant) – Benefit assessment according to §35a Social Code Book V]
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Radiofrequency catheter ablation using in-silico modelling in atrial fibrillation]
2024     Penn Medicine Center for Evidence-based Practice (CEP) Interventions to prevent aspiration pneumonia in non-ventilated hospitalized patients
2024     National Institute for Health and Care Excellence (NICE) Remdesivir and tixagevimab plus cilgavimab for treating COVID-19. NICE technology appraisal guidance 971
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (TNBC, neoadjuvant and adjuvant) – Benefit assessment according to §35a Social Code Book V (expiry of the decision)]
2024     Canary Health Service [Assessment of body composition using electrical bioimpedance for the evaluation of overweight and obesity in primary care]
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Emotional freedom technique]
2024     Scottish Health Technologies Group (SHTG) Transcatheter aortic valve implantation (TAVI) - SHTG Assessment
2024     National Institute for Health and Care Excellence (NICE) Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma in people 3 years and over. NICE technology appraisal guidance 967
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Capivasertib (breast cancer) – benefit assessment according to §35a Social Code Book V]
2024     Canary Health Service [Myofunctional therapy (oropharyngeal exercises) for obstructive sleep apnea]
2024     Scottish Health Technologies Group (SHTG) Genotype testing to guide antibiotic use and prevent hearing loss in babies - SHTG Assessment
2024     National Institute for Health and Care Excellence (NICE) Gefapixant for treating refractory or unexplained chronic cough (terminated appraisal). NICE technology appraisal guidance 969
2024     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Molecular characterization of central nervous system tumors by (next-generation sequencing, NGS). Evaluation of diagnostic and prognostic utility and implementation considerations]
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Magnetic resonance imaging-guided transurethral ultrasound ablation of localized prostate cancer]
2024     Scottish Health Technologies Group (SHTG) Artificial intelligence supported clinician review of chest x-rays from patients with suspected lung cancer - SHTG Assessment
2024     National Institute for Health and Care Excellence (NICE) Melphalan flufenamide with dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal). NICE technology appraisal guidance 968
2024     National Institute for Health and Care Excellence (NICE) Eplontersen for treating hereditary transthyretin-related amyloidosis. NICE technology appraisal guidance 1020
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Less invasive surfactant administration]
2024     Scottish Health Technologies Group (SHTG) FDG PET dementia imaging - SHTG Recommendation
2024     National Institute for Health and Care Excellence (NICE) Pembrolizumab with gemcitabine and cisplatin for untreated advanced biliary tract cancer (terminated appraisal). NICE technology appraisal guidance 966
2024     National Institute for Health and Care Excellence (NICE) Pembrolizumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer. NICE technology appraisal guidance 1017
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Axicabtagene ciloleucel (DLBCL and HGBL, second line) – Addendum to Project A24-71]
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Artificial intelligence-based diagnostic assistant test for paroxysmal atrial fibrillation using 12-lead electrocardiogram data]
2024     NIHR Health Technology Assessment programme Benefits and harms of antenatal and newborn screening programmes in health economic assessments: the VALENTIA systematic review and qualitative investigation
2024     National Institute for Health and Care Excellence (NICE) Single-step scaffold insertion for repairing symptomatic chondral knee defects. NICE interventional procedures guidance 793
2024     National Institute for Health and Care Excellence (NICE) Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis. NICE technology appraisal guidance 1018
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Alectinib (NSCLC, adjuvant) – Addendum to Project A24-73]
2024     Canary Health Service [Psychological interventions in paediatric population eligible for palliative care and their family]
2024     Ontario Health Plasma-based comprehensive genomic profiling DNA assays for non-small cell lung cancer
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Artificial intelligence-based screening test for emergent large vessel occlusion using non-contrast brain CT images]
2024     NIHR Health Technology Assessment programme Cefiderocol for treating severe aerobic Gram-negative bacterial infections: technology evaluation to inform a novel subscription-style payment model
2024     National Institute for Health and Care Excellence (NICE) Phrenic nerve pacing for congenital central hypoventilation syndrome. NICE interventional procedures guidance 790
2024     National Institute for Health and Care Excellence (NICE) Crovalimab for treating paroxysmal nocturnal haemoglobinuria in people 12 years and over. NICE technology appraisal guidance 1019
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Isavuconazole (aspergillosis) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2024     Canary Health Service [Cost-effectiveness of neonatal screening for spinal muscular atrophy and severe combined immunodeficiency]
2024     Ontario Health Single-exposure, dual-energy subtraction flat panel x-ray detectors
2024     Canadian Agency for Drugs and Technologies in Health (CADTH) Aging in place
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Monocyte distribution width, MDW]
2024     NIHR Health Services and Delivery Research programme Improving support and planning ahead for older people with learning disabilities and family carers: a mixed-methods study
2024     National Institute for Health and Care Excellence (NICE) Caval valve implantation for tricuspid regurgitation. NICE interventional procedures guidance 791
2024     National Institute for Health and Care Excellence (NICE) Elafibranor for previously treated primary biliary cholangitis. NICE technology appraisal guidance 1016
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Isavuconazole (mucormycosis) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2024     Ontario Health Interferon-gamma release assay testing for latent tuberculosis infection
2024     WorkSafeBC Safety and efficacy / effectiveness on the placement of permanent catheter for marcaine infusion to treat radial nerve injury post-de Quarvain tenosinovitis surgery: 2024 update
2024     Canadian Agency for Drugs and Technologies in Health (CADTH) Biologic drugs for severe asthma
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Gastrointestinal bleeding control using endoscopic hemostatic powder]
2024     NIHR Health Technology Assessment programme Comparison of surgical or non-surgical management for non-acute anterior cruciate ligament injury: the ACL SNNAP RCT
2024     National Institute for Health and Care Excellence (NICE) Phrenic nerve pacing for ventilator-dependent high cervical spinal cord injury. NICE interventional procedures guidance 792
2024     National Institute for Health and Care Excellence (NICE) Alectinib for adjuvant treatment of ALK-positive non-small-cell lung cancer. NICE technology appraisal guidance 1014
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Polihexanide (Acanthamoeba keratitis) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2024     Ontario Health Peripheral nerve stimulation for chronic neuropathic pain
2024     WorkSafeBC Efficacy / effectiveness of platelet rich plasma in treating Sinus Tarsi Syndrome
2024     Canadian Agency for Drugs and Technologies in Health (CADTH) Buprenorphine formulations for opioid use disorder
2024     NIHR Health Services and Delivery Research programme Service innovations for people with multiple long-term conditions: reflections of a rapid evaluation team
2024     National Institute for Health and Care Excellence (NICE) Minimally invasive percutaneous surgical techniques with internal fixation for correcting hallux valgus. NICE interventional procedures guidance 789
2024     National Institute for Health and Care Excellence (NICE) Teclistamab for treating relapsed and refractory multiple myeloma after 3 or more treatments. NICE technology appraisal guidance 1015
2024     WorkSafeBC Efficacy / effectiveness of platelet-rich plasma in treating chronic ankle sprain
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Real time high resolution MR image guidance during irradiation]
2024     NIHR Health Technology Assessment programme Laparoscopic cholecystectomy versus conservative management for adults with uncomplicated symptomatic gallstones: the C-GALL RCT
2024     National Institute for Health and Care Excellence (NICE) CYP2C19 genotype testing to guide clopidogrel use after ischaemic stroke or transient ischaemic attack. NICE diagnostics guidance 59
2024     National Institute for Health and Care Excellence (NICE) Avapritinib for treating advanced systemic mastocytosis. NICE technology appraisal guidance 1012
2024     WorkSafeBC Causal association between post-concussion syndrome and the development of myalgic encephalomyelitis / chronic fatigue syndrome
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Irreversible electroporation for renal cancer]
2024     NIHR Health Technology Assessment programme Care models for coexisting serious mental health and alcohol/drug conditions: the RECO realist evidence synthesis and case study evaluation
2024     National Institute for Health and Care Excellence (NICE) Danicopan with ravulizumab or eculizumab for treating paroxysmal nocturnal haemoglobinuria. NICE technology appraisal guidance 1010
2024     WorkSafeBC Efficacy and effectiveness of cold compression therapies post-joint surgery
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Algorithm-based Alzheimer's disease diagnosis-aided test using plasma biomarkers]